. Author manuscript; available in PMC: 2014 Sep 19.

Published in final edited form as: Invest New Drugs. 2013 Feb 10;31(4):1023–1034. doi: 10.1007/s10637-013-9935-x

Table 2. LY2181308 Plasma PK Parameters Following Day 1 and Day 3 Dosing (750-mg 3-hour Infusion).

	Day 1				Day 3
	Patient N^a	Cmax (ng/mL)	Patient N^a	Cmax (ng/mL)	Plasma CLss (L/h)	AUCτ (ng*h/mL)	Vz (L)
Group 1^c	N=8	50503 (51.0)	N=8	46822 (57.0)	3.45 (60.0)	216947 (60.0)	654 (43.4)
Group 1^c		26830 - 88137^b		20586 - 90339^b	1.56 - 7.88^b	95189 - 480259^b	376 - 1315
Group 2^c	N=15^d	45678 (28.7)	N=16	45565 (35.1)	4.04 (45.7)	185734 (45.7)	1149 (71.9)
Group 2^c		27740 - 77519^b		26497 - 80711^b	1.63 - 8.1^b	92621 - 460082^b	300 - 3430

Abbreviations: AUCτ = area under the curve over the dosing interval; CL_ss = steady state clearance; C_max = maximum concentration; N = number of enrolled patients; PS = performance status; SD = standard deviation; Vz = Volume of Distribution (calculated plasmaCLss/(0.693/t1/2), t1/2 from the model).

Number of patients.

Range.

Group 1 represents LY2181308 monotherapy; Group 2 represents LY2181308 monotherapy on Days 1 and 2, and together with chemotherapy on Day 3.

No PK data collected for 1 patient on Day 1.